AZN - AstraZeneca PLC
LSE
->
Healthcare
->
Drug Manufacturers—General
Cambridge,
United Kingdom
Type: Equity
AZN price evolution
AZN
| (in millions $) | 31 Dec 2023 | 30 Sep 2023 | 30 Jun 2023 | 1 May 2023 |
|---|---|---|---|---|
| Current assets | ||||
| Cash | $5840 | $4871 | $5664 | $6232 |
| Short term investments | $122 | $244 | $148 | $230 |
| Net receivables | $13552 | $11997 | $11932 | $10797 |
| Inventory | $5424 | $5292 | $5051 | $4967 |
| Total current assets | $25054 | $22501 | $22839 | $22266 |
| Long term investments | $1677 | $1290 | $1143 | $1234 |
| Property, plant & equipment | $10502 | $9700 | $9624 | $9599 |
| Goodwill & intangible assets | ||||
| Total noncurrent assets | ||||
| Total investments | ||||
| Total assets | $101119 | $96086 | $96543 | $96687 |
| Current liabilities | ||||
| Accounts payable | $21541 | $19723 | $19738 | $18418 |
| Deferred revenue | ||||
| Short long term debt | $6389 | $6509 | $421 | $4693 |
| Total current liabilities | $30542 | $28588 | $26375 | $24860 |
| Long term debt | $23260 | $23044 | $25119 | $27779 |
| Total noncurrent liabilities | ||||
| Total debt | ||||
| Total liabilities | $61953 | $58865 | $59127 | $60876 |
| Shareholders' equity | ||||
| Retained earnings | $1502 | -$434 | $1842 | -$1825 |
| Other shareholder equity | $2088 | $2102 | $2100 | $2090 |
| Total shareholder equity | $39166 | $37221 | $37416 | $35811 |
| (in millions $) | 31 Dec 2023 | 31 Jan 2023 | 31 Jan 2022 | 31 Dec 2020 |
|---|---|---|---|---|
| Current assets | ||||
| Cash | $5840 | $1411 | $1461 | $7832 |
| Short term investments | $122 | $64 | $53 | $160 |
| Net receivables | $13552 | $11252 | $8795 | $5651 |
| Inventory | $5424 | $4699 | $8983 | $4024 |
| Total current assets | $25054 | $22593 | $26244 | $19544 |
| Long term investments | $1677 | $1142 | $1262 | $1147 |
| Property, plant & equipment | $10502 | $9449 | $10171 | $8917 |
| Goodwill & intangible assets | ||||
| Total noncurrent assets | $47185 | |||
| Total investments | ||||
| Total assets | $101119 | $96483 | $105363 | $66729 |
| Current liabilities | ||||
| Accounts payable | $21541 | $19040 | $2824 | $2350 |
| Deferred revenue | ||||
| Short long term debt | $6389 | $1538 | $2892 | $2386 |
| Total current liabilities | $30542 | $26293 | $22594 | $20307 |
| Long term debt | $23260 | $23690 | $28888 | $17994 |
| Total noncurrent liabilities | $30784 | |||
| Total debt | ||||
| Total liabilities | $61953 | $59446 | $66095 | $51107 |
| Shareholders' equity | ||||
| Retained earnings | $1502 | $1495 | $3755 | $7323 |
| Other shareholder equity | $2088 | -$1604 | $130 | $2040 |
| Total shareholder equity | $39166 | $37058 | $39287 | $15622 |
| (in millions $) | 31 Dec 2023 | 30 Sep 2023 | 30 Jun 2023 | 31 Mar 2023 |
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | $12024 | $11492 | $11416 | $10879 |
| Cost of revenue | $2295 | $2055 | $1917 | $1773 |
| Gross Profit | $9729 | $9437 | $9499 | $9106 |
| Operating activities | ||||
| Research & development | $3352 | $2534 | $2627 | $2308 |
| Selling, general & administrative | $5468 | $4440 | $5054 | $4150 |
| Total operating expenses | $11720 | $8959 | $8814 | $8192 |
| Operating income | $304 | $2533 | $2602 | $2687 |
| Income from continuing operations | ||||
| EBIT | ||||
| Income tax expense | -$62 | $274 | $268 | $458 |
| Interest expense | -$445 | -$392 | -$431 | -$365 |
| Net income | ||||
| Net income | $960 | $1374 | $1818 | $1803 |
| Income (for common shares) | $960 | $1374 | $1803 | |
| (in millions $) | 31 Dec 2023 | 31 Dec 2022 | 31 Dec 2021 | 31 Dec 2020 |
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | $45811 | $44351 | $37417 | $26617 |
| Cost of revenue | $8040 | $8619 | $9799 | $5270 |
| Gross Profit | $37771 | $35732 | $27610 | $21347 |
| Operating activities | ||||
| Research & development | $10716 | $9529 | $8021 | $6094 |
| Selling, general & administrative | $18602 | $17653 | $9338 | |
| Total operating expenses | $37107 | $35388 | $21455 | |
| Operating income | $8704 | $8963 | $5343 | $5162 |
| Income from continuing operations | ||||
| EBIT | ||||
| Income tax expense | $938 | -$792 | -$380 | $772 |
| Interest expense | -$1626 | -$1346 | -$776 | |
| Net income | ||||
| Net income | $5955 | $3288 | $112 | $3196 |
| Income (for common shares) | $5955 | $3288 | $112 | $3196 |
| (in millions $) | 31 Dec 2023 | 30 Sep 2023 | 30 Jul 2023 | 31 Mar 2023 |
|---|---|---|---|---|
| Net income | $960 | $1374 | $1803 | |
| Operating activities | ||||
| Depreciation | $320 | $268 | $260 | |
| Business acquisitions & disposals | ||||
| Stock-based compensation | ||||
| Total cash flows from operations | $2380 | $3114 | $3133 | |
| Investing activities | ||||
| Capital expenditures | -$525 | -$319 | -$247 | |
| Investments | ||||
| Total cash flows from investing | -$1077 | -$1221 | -$1766 | -$1246 |
| Financing activities | ||||
| Dividends paid | -$2 | -$1410 | -$3069 | -$3047 |
| Sale and purchase of stock | $21 | $4 | $4 | |
| Net borrowings | -$310 | -$1274 | $1852 | |
| Total cash flows from financing | -$291 | -$2726 | -$3550 | -$2031 |
| Effect of exchange rate | -$47 | |||
| Change in cash and equivalents | $1018 | -$852 | -$512 | -$155 |
| (in millions $) | 31 Dec 2023 | 31 Dec 2022 | 31 Dec 2021 | 31 Dec 2020 |
|---|---|---|---|---|
| Net income | $5955 | $3288 | $112 | $3916 |
| Operating activities | ||||
| Depreciation | $1107 | $1098 | $4039 | $3149 |
| Business acquisitions & disposals | ||||
| Stock-based compensation | ||||
| Total cash flows from operations | $10345 | $9808 | $5963 | $4799 |
| Investing activities | ||||
| Capital expenditures | -$1361 | -$1091 | -$1091 | -$2606 |
| Investments | ||||
| Total cash flows from investing | -$4064 | -$2960 | -$11058 | -$285 |
| Financing activities | ||||
| Dividends paid | -$4481 | -$4364 | -$3856 | -$3572 |
| Sale and purchase of stock | $33 | $29 | $29 | $30 |
| Net borrowings | -$1233 | -$1441 | $7654 | $1440 |
| Total cash flows from financing | -$6567 | -$6823 | $3649 | -$2203 |
| Effect of exchange rate | -$16 | -$20 | $12 | |
| Change in cash and equivalents | -$346 | -$55 | -$1508 | $2323 |
News
Fundamentals
| Market cap | $34.80T |
|---|---|
| Enterprise value | N/A |
| Shares outstanding | 3.07B |
| Revenue | $45.81B |
|---|---|
| EBITDA | N/A |
| EBIT | N/A |
| Net Income | $5.96B |
| Revenue Q/Q | 7.29% |
| Revenue Y/Y | 3.29% |
| P/E ratio | 5.84K |
|---|---|
| EV/Sales | N/A |
| EV/EBITDA | N/A |
| EV/EBIT | N/A |
| P/S ratio | 759.54 |
| P/B ratio | 938.43 |
| Book/Share | 12.10 |
| Cash/Share | 1.91 |
| EPS | $1.94 |
|---|---|
| ROA | 6.10% |
| ROE | 15.92% |
| Debt/Equity | 1.58 |
|---|---|
| Net debt/EBITDA | N/A |
| Current ratio | 0.82 |
| Quick ratio | 0.64 |